Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
about
Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant allelesLow-grade sulfadoxine-pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, AngolaMolecular monitoring of Plasmodium falciparum super-resistance to sulfadoxine-pyrimethamine in TanzaniaOrigin and evolution of sulfadoxine resistant Plasmodium falciparumSubmicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western KenyaHigh resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malariaA database of antimalarial drug resistance.Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum.Immunity as a predictor of anti-malarial treatment failure: a systematic reviewProtective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance.Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, MalawiDrug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.Molecular surveillance of pvdhfr, pvdhps, and pvmdr-1 mutations in Plasmodium vivax isolates from Yunnan and Anhui provinces of ChinaTwo novel mutations of pfdhps K540T and I588F, affecting sulphadoxine-pyrimethamine-resistant response in uncomplicated falciparum malaria at Banjar district, South Kalimantan Province, Indonesia.Prescription patterns and drug use among pregnant women with febrile Illnesses in Uganda: a survey in out-patient clinics.Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania.Drug resistance maps to guide intermittent preventive treatment of malaria in African infants.The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP+artesunate combination.Media, health workers, and policy makers' relationship and their impact on antimalarial policy adoption: a population genetics perspective.Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana.Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in childrenThe usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New GuineaIs sulphadoxine-pyrimethamine (SP) still useful as the first-line antimalarial drug in Malawi or it must be quickly withdrawn from the antimalarial repertoire?Detection of the dihydrofolate reductase-164L mutation in Plasmodium falciparum infections from Malawi by heteroduplex tracking assay.Folic acid metabolism and malaria.Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal.Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East.Monitoring antifolate resistance in intermittent preventive therapy for malaria.Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance.Low prevalence of the molecular markers of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in asymptomatic children in Northern Benin.In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation.Polymorphism in dhfr/dhps genes, parasite density and ex vivo response to pyrimethamine in Plasmodium falciparum malaria parasites in Thies, Senegal.Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling.Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86.A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania.Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine/pyrimethamine in pregnant women in Yaoundé, Cameroon: emergence of highly resistant pfdhfr/pfdhps alleles.
P2860
Q28125916-61826E58-24BE-4D44-8FE2-877F04B87E6BQ28125937-20585C99-ABE5-4FB5-8C0A-8ADC86BAB505Q28125938-C5F6BE5A-1A0D-45AB-96A8-012ADC118A72Q28473479-67860F4B-33E3-4A27-8032-E50B87B83830Q28474692-8F262691-29D4-4E75-AFFE-C222DE727280Q28474860-8D847D8E-3F3B-40C5-AA6F-022F2A56FF05Q28475195-CF3CC1D0-B842-4F8F-8C00-E109BA5A5244Q30483123-9660B61D-7362-409B-8A03-9ED6E83DB3E2Q30541962-0AD84F38-244B-402E-992F-786CCCF0C833Q33582154-7961A2B3-D6D2-4A90-A374-936299A3B4A1Q33691573-357B37DA-E292-4830-A9A5-6C04B2FFFCC7Q33935361-75B1B079-4489-468E-BA7C-FA89909B7EC2Q34014169-CD344811-96B8-49E0-A09A-599CC8D73AF8Q34168392-070569BA-8FFC-420E-84D8-1650646DE8D9Q34465026-8C4C02D8-DC70-40E5-A619-26DFD7984CA4Q34736220-68D7FDE5-23C3-4DF4-9A77-5AAF84FE3765Q35171924-91054FA4-6530-44B4-94B1-8432C5AB5EA9Q35228689-94DB7714-5056-47C0-8DB0-621325B0FBC2Q35541212-DA8EAEB0-8FDF-44DA-85CA-99ED47DE8A28Q35755266-75A121FD-B36E-4696-99AC-3792950E1AC9Q36450234-C2BF85F9-A558-426C-A2F6-264C6D808E02Q36593867-AA815CC5-5BF0-41A8-9524-1CDB6078CD75Q36649305-CB086518-2A86-4C05-A813-460609087845Q36736814-54E24B8A-BAC9-4EB6-83BC-328524D049ACQ37012863-EDEBBAB4-EDD4-498B-86CE-AC57947F9920Q37093779-3E1F0384-0191-49DD-9295-2DA1C013BDC7Q37119559-B07A8177-9C70-4F2C-998C-B77EA00EBE3AQ37121527-66ECA51C-5861-4FD0-987C-183C270A0E13Q37260585-0D567468-22B8-453E-929A-E759F7F57A5DQ37323427-1C9A8293-39F2-4B35-9D6B-9BCD8B7FDBB2Q37326702-73F0D4FB-6775-48AB-A0C9-26B5FC33F72CQ37333178-364A3D51-CDEE-4630-AA7C-FC05DF48B316Q37390524-AF312677-7994-40C9-82A5-B95280F87247Q38636047-64FF7F99-78E8-4E12-AA49-87D4D7C8D7EFQ38752586-7CA226A9-0467-4026-BE28-AC30A9F15314Q39257141-9AAF0B37-BBA5-43DD-B7E7-C849CC99D66FQ39257152-C846CE16-5257-41E9-855C-01DDD2FBA8E4Q39345222-D46EC08B-427A-47D6-885D-0DF264EBF638Q39363372-E719178A-4475-4587-9E2F-F193C61FFA19Q41157564-2277EF61-25E7-4D17-9CF4-9363B4B8753C
P2860
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Relationship between age, mole ...... treatment in Kampala, Uganda.
@en
type
label
Relationship between age, mole ...... treatment in Kampala, Uganda.
@en
prefLabel
Relationship between age, mole ...... treatment in Kampala, Uganda.
@en
P2860
P50
P921
P1476
Relationship between age, mole ...... treatment in Kampala, Uganda.
@en
P2093
Hakim Sendagire
Steven Lamola
P2860
P304
P356
10.1111/J.1365-3156.2004.01239.X
P577
2004-05-01T00:00:00Z